Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Jazz Pharmaceuticals Partners with AbCellera for T Cell Engager Development

Jazz Pharmaceuticals has entered into a collaboration with AbCellera to discover and develop next-generation T cell engagers for various gastrointestinal cancers and other solid tumors. The deal includes an upfront payment of $56 million to AbCellera. For each of the three initial programs, AbCellera could receive up to $792 million in milestone payments, plus tiered royalties, bringing the total potential deal value to approximately $2.46 billion. This partnership aims to leverage AbCellera’s multispecific T cell engager platform to advance novel cancer treatments.

• The financial terms of the collaboration include an upfront payment of $56 million to AbCellera. For each of the three initial programs, AbCellera is eligible to receive up to $792 million in milestone payments, plus tiered royalties. An additional $28 million will be paid to AbCellera when work on the third discovery program commences, contributing to a total potential deal value of up to $2.46 billion.
• This partnership focuses on leveraging AbCellera’s multispecific T cell engager (TCE) platform for discovery and early-stage research. The primary therapeutic goal is to develop novel candidates for multiple gastrointestinal (GI) cancers and other solid tumors, targeting hard-to-treat cancers where current treatment options are limited or fall short.
• The collaboration strategically aligns with Jazz Pharmaceuticals’ efforts to diversify its oncology portfolio, specifically expanding its focus on GI cancers and building on existing expertise. This move underscores Jazz’s ongoing business development activity, reinforcing a balanced-portfolio thesis following recent news regarding its Zepzelca trial and its existing Ziihera program.

Addressing Unmet Needs in Hard-to-Treat GI Cancers

Gastrointestinal cancers collectively account for over 30% of global cancer-related mortality, with more than 5 million new cases and 3.5 million deaths recorded in 2020 alone — a burden projected to increase further by 2040. Despite incremental advances in chemotherapy, immunotherapy, and targeted therapy, critical gaps persist across diagnosis, patient selection, and treatment efficacy. The following points outline the principal unmet needs and underserved populations driving current research and clinical development priorities.

• Late-stage diagnosis remains a systemic barrier: The majority of gastric cancer patients are diagnosed at advanced or metastatic stages due to the absence of specific early symptoms and limited screening infrastructure, particularly in Western countries. Endoscopic screening — the gold standard for early detection — is logistically and economically feasible only in select high-incidence regions, leaving most patients without timely intervention.

• Survival outcomes remain deeply unsatisfactory: Despite the integration of immune checkpoint inhibitors (ICIs) and targeted agents into first-line regimens, median survival for advanced gastric cancer remains approximately one year, with a 1-year overall survival rate of only ~55% under current standard-of-care combinations. Drug resistance and post-treatment toxicity are the primary drivers of persistent high mortality across GI malignancies.

• Biomarker discovery and patient selection are critically underdeveloped: There is an urgent unmet need to identify validated predictive biomarkers beyond PD-L1 expression to improve patient selection for ICIs and targeted therapies. Tumor heterogeneity, the complexity of the GI tumor microenvironment, and limited understanding of molecular drivers of proliferation collectively constrain the development of precision treatment strategies.

• Specific patient subpopulations remain therapeutically underserved:

  • Patients with brain metastases from gastric cancer — representing ~1% of diagnoses — face a median overall survival of only 8 months with few viable conventional treatment options.

  • Only ~5% of metastatic colorectal cancer patients (those with MSI-H status) derive meaningful benefit from ICIs; the remaining majority lack effective immunotherapy options.

  • Patients in low and lower-middle SDI countries — particularly in East Asia and Sub-Saharan Africa — bear the highest burden of gastric and esophageal cancers, yet face the most pronounced inequities in care quality, with females disproportionately affected.

• Drug resistance constitutes a growing therapeutic obstacle: The expanded application of cytotoxic and targeted anti-cancer agents has generated a widening spectrum of resistance mechanisms in GI cancers, limiting the durability of response and rendering existing chemotherapy regimens increasingly inadequate in terms of recurrence prevention and survival prolongation.

• Novel molecular targets and combination strategies are still being defined: Emerging targets — including CLDN18.2, FGFR2b, and previously "undruggable" RAS pathway components — are under active investigation. However, optimizing combination regimens across cytotoxic, targeted, and immunotherapeutic modalities, while managing adverse events and immune resistance, remains an unresolved clinical and translational challenge.

T Cell Engagers: An Emerging Frontier in GI Oncology

The therapeutic landscape for gastrointestinal and solid tumors has undergone significant expansion over the past three years, with multiple mechanistically distinct approaches advancing from preclinical models into clinical evaluation. These emerging modalities span immune modulation, metabolic reprogramming, targeted oncogenic pathway inhibition, and microenvironmental remodeling — reflecting the biological complexity of GI malignancies.

• Immune Checkpoint Inhibition: PD-1 antibodies pembrolizumab and nivolumab are now approved for first-line treatment of PD-L1-positive gastric cancer, supported by survival and response improvements demonstrated in CheckMate-649 and KEYNOTE-859. Combination strategies pairing immune checkpoint inhibition with anti-HER2 therapy (KEYNOTE-811) and perioperative chemotherapy regimens (DANTE, KEYNOTE-585, MATTERHORN) have shown promising pathological remission rates. PDK inhibition has also been identified as a mechanism to upregulate PD-L1 expression via histone acetylation, potentially broadening checkpoint blockade applicability.

• HER2-Targeted Therapies: Beyond trastuzumab-based first-line regimens, the antibody-drug conjugate trastuzumab-deruxtecan (T-DXd) has emerged as a promising second-line option following trastuzumab failure, while the bispecific antibody zanidatamab demonstrates early efficacy in first-line settings. Small-molecule tyrosine kinase inhibitors such as lapatinib and pyrotinib offer complementary advantages including oral bioavailability and blood-brain barrier penetration.

• CLDN18.2 and FGFR2b Targeting: Zolbetuximab, an anti-claudin 18.2 (CLDN18.2) antibody, demonstrated superior survival outcomes versus chemotherapy alone in CLDN18.2-positive first-line gastric cancer, with regulatory approval anticipated in 2024. Novel FGFR2b-directed therapies are also showing early clinical promise as molecularly selected treatment options.

• Metabolic Pathway Reprogramming: Pyruvate dehydrogenase kinase (PDK) inhibition has emerged as a strategy to shift tumor metabolism away from glycolysis, increase acetyl-CoA-driven histone acetylation, and sensitize tumors to immunotherapy. In colorectal cancer, the bifunctional immunometabolic prodrug T26 — linking a glutamine antagonist (JHU083) with STING agonist MSA-2 — restores dendritic cell maturation and CD8⁺ T cell activation by reversing glutamine depletion in the tumor microenvironment, demonstrating synergy with chemotherapy and checkpoint blockade without systemic toxicity.

• Tumor Microenvironment (TME) Modulation: The TME is increasingly recognized as a central driver of drug resistance in GI cancers, with crosstalk between tumor cells, cancer stem cells, tumor-associated stromal cells, and extracellular vesicles sustaining immune evasion and therapeutic failure. CCL28-CCR10 signaling has been identified as a mechanism by which tumor cells recruit and modulate plasma cells, suppressing CD8⁺ T cell infiltration; targeting CCL28 has shown synergistic potential with immunotherapy across multiple preclinical tumor models. Tertiary lymphoid structures (TLSs) are also emerging as prognostically significant TME features associated with improved immunotherapy response.

• PROTAC-Based CDK4/6 Degradation: pH- and cathepsin B-responsive nanoparticles (PSRNs) have been engineered to deliver CDK4/6-targeting PROTACs selectively within the acidic tumor microenvironment. Intracellular CDK4/6 degradation upregulates PD-L1 expression in cancer cells and suppresses regulatory T cell proliferation, thereby augmenting the efficacy of immune checkpoint blockade in colorectal cancer preclinical models.

• Microbiome-Mediated Mechanisms: Intratumoral and gut microbiota dysbiosis is now recognized as a mechanistically active contributor to GI tumorigenesis, immune evasion, and chemotherapy resistance. Microbial metabolites — including short-chain fatty acids, indoles, and bile acids — modulate inflammation, DNA damage, and immune surveillance. In pancreatic cancer, IPMN-associated bacteria (notably Gammaproteobacteria) metabolically attenuate the cytotoxic effects of 5-fluorouracil and gemcitabine via pyrimidine metabolism pathway enrichment. Bacterial extracellular vesicles further reshape the TME, influencing immunosuppression and metastatic potential.

• Novel Oncogenic Signaling Targets: ZG16B has been identified as a pleiotropic tumor regulator upregulated across pancreatic, colorectal, gastric, and ovarian cancers, activating Toll-like receptor, CXCR4, β-catenin, and focal adhesion kinase pathways while enhancing myeloid-derived suppressor cell and M2 macrophage immunosuppressive function. ZG16B-specific strategies — including monoclonal antibodies (PBP1510 in clinical trial for advanced pancreatic cancer) and RNA aptamers — are under active investigation. Separately, exosomal LINC01614 has been shown to promote M2 macrophage polarization and Treg-driven IL-4 secretion via the JAK-STAT3 pathway, implicating non-coding RNA–mediated immune reprogramming as a therapeutically relevant mechanism in gastric cancer.

Jazz's Pipeline Diversification in the Evolving GI Cancer Landscape

Investigational agents targeting gastrointestinal (GI) cancers and solid tumors span a broad mechanistic landscape, reflecting the biological complexity of these malignancies. Across the clinical trial literature, three mechanisms of action emerge with particular prominence among unapproved drugs: KRAS pathway inhibition, matrix metalloproteinase (MMP) inhibition, and histone deacetylase (HDAC) inhibition.

• KRAS pathway targeting (direct and indirect inhibition): KRAS inhibitors represent one of the most extensively investigated mechanistic classes in GI oncology trials. Direct inhibitors such as sotorasib and adagrasib, while FDA-approved for KRAS G12C-mutant non-small cell lung cancer, have demonstrated considerably reduced efficacy in colorectal cancer harboring the same mutation. Indirect KRAS targeting—via upstream receptor tyrosine kinase inhibition or downstream MEK and PI3K blockade—has been evaluated across pancreatic and colorectal cancer settings, though monotherapy and combination regimens with chemotherapy have largely failed to improve survival in pancreatic cancer. Preclinical work combining inhibition of PAK7, MAP3K7, and CK2 survival kinases has shown cumulative apoptosis induction in pancreatic cancer models, suggesting potential for rational combination strategies.

• Matrix metalloproteinase (MMP) inhibition: MMPs are zinc-dependent proteinases that degrade the extracellular matrix, facilitating tumor invasion and metastasis—making them a logical therapeutic target in solid tumors. Despite this rationale, the majority of clinical trials evaluating MMP inhibitors (MMPIs) have yielded disappointing outcomes, with failures attributed to suboptimal study design, inappropriate patient staging, and insufficient target selectivity. Notable exceptions include positive signals observed with marimastat in gastric cancer and metastat in Kaposi's sarcoma, suggesting that patient selection and selectivity profiles remain critical determinants of activity in this class.

• Histone deacetylase (HDAC) inhibition: HDAC inhibitors act by modulating the functional equilibrium between histone acetylation and deacetylation, a balance that governs chromatin architecture and gene expression—processes frequently dysregulated in GI malignancies. In gastric cancer specifically, elevated HDAC expression has been associated with advanced disease stage, increased tumor invasion, nodal and distant metastases, and diminished overall survival. HDAC inhibitors have demonstrated capacity to induce cell cycle arrest and apoptosis in tumor cells, and importantly, exhibit synergistic interactions with standard chemotherapy regimens, positioning them as promising components of combination treatment strategies for gastric cancer.

Jazz's Strategic Leap into Next-Gen Solid Tumor Immunotherapy

Jazz Pharmaceuticals' recent collaboration with AbCellera marks a pivotal moment in its strategic evolution, signaling a robust expansion into the cutting-edge realm of T cell engager immunotherapies. While Jazz has a strong foundation in hematologic oncology with products like Vyxeos for acute myeloid leukemia and involvement in therapies for acute lymphoblastic leukemia, and a significant presence in neuroscience with sleep disorder treatments, this partnership propels the company into a new frontier: next-generation treatments for gastrointestinal and other solid tumors.

T cell engagers represent a highly promising class of biologics designed to harness the body's own immune system to fight cancer. By creating multispecific antibodies that can simultaneously bind to cancer cells and T cells, these therapies aim to bring immune cells directly to the tumor, initiating a potent anti-cancer response. This approach holds particular significance for solid tumors, which often present complex microenvironments that can hinder traditional immunotherapies. The substantial financial commitment, including an upfront payment and potential milestone payments, underscores the high stakes and perceived value of AbCellera's platform and the potential for these novel agents to address significant unmet needs.

However, this strategic move is not without its considerations. The T cell engager landscape is highly competitive, with numerous players vying for leadership in this innovative space. Jazz will need to navigate this crowded field, ensuring its candidates offer distinct advantages in terms of efficacy, safety, or target specificity. Furthermore, while the science is compelling, the clinical development of novel immunotherapies, especially for diverse solid tumors, carries inherent risks. The journey from discovery to market is long and costly, and the ultimate success of these programs will depend on robust clinical data demonstrating superior outcomes. This collaboration positions Jazz for potential long-term growth in oncology, but careful execution and differentiation will be paramount.